Brief: Vivesto Announces Positive Preclinical Data For Cantrixil In Hematological Cancer
01/04/2025 07:05
April 1 (Reuters) - Vivesto AB VIVE.ST: ANNOUNCES POSITIVE PRECLINICAL DATA FOR CANTRIXIL IN HEMATOLOGICAL CANCER CANTRIXIL TREATMENT WELL TOLERATED AND SAFE Source text: ID:nMFNbn4Kht Further company coverage: VIVE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Vivesto AB
See all newsBrief: Vivesto Reports Positive Topline Results From Paccal Vet Study In Cats
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO